MedTrace Logo

Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients

NCT05699109 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 127

Last updated 2023-01-26

No results posted yet for this study

Summary

This observational study aims to compare long-acting darbepoetin alpha versus short-acting epoetin alpha erythropoietin-stimulating agents in Egyptian hemodialysis patients. The main questions aim to answer are:

* What are the effectiveness and safety of long- acting versus short-acting erythropoietin-stimulating agents in Egyptian hemodialysis patients?
* What is the cost-effectiveness of long- acting versus short-acting erythropoietin-stimulating agents in Egyptian hemodialysis patients?

Participants will be divided into 2 groups; epoetin alfa (short-acting ESA), Eprex group, and darbepoetin alfa (long-acting ESA), Aranesp group for six month study period.

Conditions

  • Anemia of Chronic Kidney Disease
  • Chronic Renal Failure
  • Chronic Renal Failure Anemia

Sponsors & Collaborators

  • Helwan University

    lead OTHER

Principal Investigators

  • Abdel-Hameed Ibrahim Ebid, Professor · Faculty of Pharmacy, Helwan University

  • Amira Mohamed El-Sawy, Lecturer · Faculty of Pharmacy, Helwan University

  • Hazem Ayoub, Lecturer · Faculty of Medicine, Al Azhar University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05699109 on ClinicalTrials.gov